Shuhei Yoshida Net Worth

The estimated Net Worth of Shuhei Yoshida is at least $18.7 ezer dollars as of 14 May 2019. Shuhei Yoshida owns over 33,334 units of Eyenovia Inc stock worth over $18,667 and over the last 7 years Shuhei sold EYEN stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Shuhei Yoshida EYEN stock SEC Form 4 insiders trading

Shuhei has made over 2 trades of the Eyenovia Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Shuhei exercised 33,334 units of EYEN stock worth $65,001 on 14 May 2019.

The largest trade Shuhei's ever made was buying 100,000 units of Eyenovia Inc stock on 29 January 2018 worth over $1,000,000. On average, Shuhei trades about 66,667 units every 235 days since 2018. As of 14 May 2019 Shuhei still owns at least 33,334 units of Eyenovia Inc stock.

You can see the complete history of Shuhei Yoshida stock trades at the bottom of the page.

What's Shuhei Yoshida's mailing address?

Shuhei's mailing address filed with the SEC is C/O EYENOVIA, INC., 295 MADISON AVENUE, SUITE 2400, NEW YORK, NY, 10017.

Insiders trading at Eyenovia Inc

Over the last 7 years, insiders at Eyenovia Inc have traded over $1,275,000 worth of Eyenovia Inc stock and bought 6,072,235 units worth $17,599,075 . The most active insiders traders include Ernest Mario, Stuart M. Grant és Fredric N Eshelman. On average, Eyenovia Inc executives and independent directors trade stock every 31 days with the average trade being worth of $49,678. The most recent stock trade was executed by Michael M Rowe on 28 August 2024, trading 27,071 units of EYEN stock currently worth $14,077.

What does Eyenovia Inc do?

eyenovia, inc. (nasdaq: eyen) is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for microdosing. eyenovia’s pipeline is currently focused on the late-stage development of microdosed medications for myopia progression, presbyopia, mydriasis and other eye diseases.

Complete history of Shuhei Yoshida stock trades at Eyenovia Inc

Eyenovia Inc executives and stock owners

Eyenovia Inc executives and other stock owners filed with the SEC include:

• Tsontcho Ianchulev,
  Chief Executive Officer, Director, Chief Medical Officer
• Dr. Tsontcho Ianchulev M.P.H., M.D., MPH,
  CEO, Pres, Chief Medical Officer & Director
• John Gandolfo,
  Chief Financial Officer, Secretary
• John P. Gandolfo CPA,
  CFO & Sec.
• Michael Rowe,
  Vice President - Commercial
• Jennifer Clasby,
  Vice President - Clinical Operations
• Michael M. Rowe,
  Chief Operating Officer
• Fredric Eshelman,
  Independent Chairman of the Board
• Tram Bui,
  IR Contact Officer
• Anthony Sun,
  Independent Director
• Charles Mather,
  Independent Director
• Ernest Mario,
  Independent Director
• Kenneth Lee,
  Independent Director
• Curt Labelle,
  Director
• Luke Clauson,
  Vice President - Research &Development and Manufacturing
• Norbert Lowe,
  VP of Sales & Marketing
• Alexander Lobo,
  Investor Contact
• Andrew D. Jones,
  Chief Financial Officer
• Julia A Haller,
  
• Bren Kern,
  Chief Operating Officer
• Pharmaceutical Co., Ltd. Senju,
  10% owner
• Shuhei Yoshida,
  Director
• Stuart M. Grant,
  
• Stephen Keith Benjamin,
  
• Rachel Jacobson,
  Director
• Ellen R Strahlman,
  Director
• Michael S Geltzeiler,
  Director
• Ram Palanki,
  Director